Raimondi A, et al. - In this single-center prospective single-arm trial, researchers tested the safety and effectiveness of metronomic capecitabine plus cyclophosphamide regimen in unresectable or relapsed pseudomyxoma peritonei (PMP). Inclusion criteria were PMP, unresectable or progressive to surgery/previous treatments, which were histologically confirmed. Until progression, unacceptable toxicity or consent withdrawal, patients received a continuous metronomic regimen with capecitabine (625 mg/sqm BID) plus cyclophosphamide (50 mg/day). Progression-free survival (PFS) was the primary endpoint. Disease control rate (DCR), overall survival (OS) and safety were secondary endpoints. From April 2015 to October 2017, 23 consecutive patients were enrolled. Investigators found that median PFS was 9.5 months and 1-year OS rate was 73.7% at a median follow up of 22.4 months. Overall, DCR was 87% and 27% subjects achieved a disease control ≥12 months. According to findings, metronomic capecitabine plus cyclophosphamide in unresectable/recurrent PMP is a well-tolerated regimen and its safety profile compares favorably with previously investigated regimens.